- Global Pharma News & Resources

Fidia Announces Presentation of New Data Evaluating HYMOVIS® (HYADD®4) Effects on Metalloprotease Inhibition at 2018 ACR/ARHP Annual Meeting

Fidia Farmaceutici S.p.A., a world leader in the research, development and manufacturing of hyaluronic acid (HA)-based products and its wholly owned subsidiary, Fidia Pharma USA Inc., announce that new data will be presented at the 2018 ACR/ARHP Annual Meeting in Chicago, Illinois, October 19-24, 2018.

Fidia Farmaceutici S.p.A. conducted in vitro, ex vivo and in silico testing to determineHYADD®4 as a metalloprotease (MMP) inhibitor. Matrix metalloprotease-3 (MMP3) is a cartilage degrading enzyme and may be a promising target in osteoarthritis (OA) therapy. Several clinical studies reported an increase of MMP3 level in synovial fluid (SF) in early and advanced OA patients.

This new study was conducted to further evaluate the results obtained in previous work where the hyaluronic acid (HA) partial hexadecylamide (HYADD®4), contained in the viscosupplement Hymovis®, was shown to have relevant MMP and hyaluronidase inhibition activity. In this study, HYADD®4 confirmed an inhibitory effect on the activity of a large set of MMPs and namely, it showed the highest inhibition potency against MMP13, MMP8 and MMP3.*

The new data will be presented at the 2018 ACR/ARHP Annual Meeting in Chicago, Illinois, on Tuesday, October 23, 2018:

*Preclinical studies may not be indicative of human clinical outcomes.


HYMOVIS®is a highly viscoelastic non-crosslinked hydrogel bioengineered using a proprietary process that increases lubrication and shock absorption properties. This results in a natural hyaluronan similar to the hyaluronan found in the synovial fluid present in human joints. The formulation allows this unique molecule to recover its original structure, even after repetitive mechanical stress. Due to reversible hydrophobic interactions, the non-crosslinked HYMOVIS®has increased elasticity, viscosity and residence time in the joint.* Its unique molecular structure results in enhanced biomechanical properties and long-lasting efficacy, all in a convenient two-dose regimen.

In the U.S., HYMOVIS® is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy or simple analgesics.

HYMOVIS® is contraindicated in patients with known hypersensitivity to hyaluronate preparations or gram-positive bacterial proteins or patients with infections/skin diseases in the area of the injection site/joint. The safety and effectiveness of HYMOVIS® has not been tested in pregnant women, nursing mothers or children. See package insert for full prescribing information including adverse events, warnings, precautions, and side effects at

Rx Only. HYMOVIS® and HYADD®4 are registered trademarks of Fidia Farmaceutici S.p.A., Abano Terme, Italy. ©2018 Fidia Pharma USA Inc., Florham Park, N.J., a wholly owned subsidiary of Fidia Farmaceutici S.p.A. FID685-10.2018

About Fidia Farmaceutici

Fidia Farmaceutici is part of Fidia Pharma Group, an Italian multinational company, with R&D, manufacturing and sales capabilities, and an extensive product portfolio mainly based on natural and functionalized hyaluronic acid (over 700 patents), in joint care, wound healing, ophthalmology, aesthetic and regenerative medicine. Manufacturing operations, located in Italy, are inspected by major international health authorities, and the company extends its global reach through wholly-owned subsidiaries and commercial partners in 100 countries worldwide. For more information, please visit

View source version on

Editor Details

Last Updated: 23-Oct-2018